{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:25:06Z","timestamp":1794317106538,"version":"4.9.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.humpath.2026.106281","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:23:13Z","timestamp":1792020193000},"page":"106281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aberrant HER2 expression as a specific and feasible diagnostic marker for fumarate hydratase-deficient renal cell carcinoma"],"prefix":"10.1016","author":[{"given":"Jue","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linmao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxiang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1405-4208","authenticated-orcid":false,"given":"Yuyan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3165-4280","authenticated-orcid":false,"given":"Xueqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0628-0723","authenticated-orcid":false,"given":"Ni","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2026.106281_bib1","series-title":"Fumarate hydratase-deficient renal cell carcinoma","first-page":"78","article-title":"Urinary and male genital tumours","year":"2022"},{"key":"10.1016\/j.humpath.2026.106281_bib2","series-title":"Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated renal cell carcinoma","first-page":"25","article-title":"Urinary and male genital tumours","year":"2016"},{"issue":"10","key":"10.1016\/j.humpath.2026.106281_bib3","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1158\/1078-0432.CCR-20-4367","article-title":"Comprehensive molecular characterization and response to therapy in fumarate hydratase-deficient renal cell carcinoma","volume":"27","author":"Gleeson","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.humpath.2026.106281_bib4","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/PAS.0000000000001372","article-title":"A clinicopathologic and molecular analysis of fumarate hydratase-deficient renal cell carcinoma in 32 patients","volume":"44","author":"Lau","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.humpath.2026.106281_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100303","article-title":"AKR1B10 is a new sensitive and specific marker for fumarate hydratase-deficient renal cell carcinoma","volume":"36","author":"Zheng","year":"2023","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.humpath.2026.106281_bib6","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41379-018-0017-7","volume":"31","author":"Muller","year":"2018","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2026.106281_bib7","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1038\/s41467-025-59513-8","article-title":"Comprehensive molecular profiling of FH-deficient renal cell carcinoma identifies molecular subtypes and potential therapeutic targets","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat Commun"},{"issue":"53","key":"10.1016\/j.humpath.2026.106281_bib8","doi-asserted-by":"crossref","first-page":"6102","DOI":"10.1038\/sj.onc.1203973","article-title":"Molecular mechanisms underlying ErbB2\/HER2 action in breast cancer","volume":"19","author":"Harari","year":"2000","journal-title":"Oncogene"},{"issue":"22","key":"10.1016\/j.humpath.2026.106281_bib9","first-page":"6221","article-title":"Aberrant expression of epidermal growth factor receptor and HER-2 (erbB-2) messenger RNAs in human renal cancers","volume":"49","author":"Freeman","year":"1989","journal-title":"Cancer Res"},{"issue":"15","key":"10.1016\/j.humpath.2026.106281_bib10","first-page":"4504","article-title":"Inverse relationship of epidermal growth factor receptor and HER2\/neu gene expression in human renal cell carcinoma","volume":"50","author":"Weidner","year":"1990","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.humpath.2026.106281_bib11","article-title":"ERBB2 is a potential diagnostic and prognostic biomarker in renal clear cell carcinoma","volume":"14","author":"Gao","year":"2024","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.humpath.2026.106281_bib12","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3892\/ol.2012.727","article-title":"HER2 expression in renal cell carcinoma is rare and negatively correlated with that in normal renal tissue","volume":"4","author":"Wang","year":"2012","journal-title":"Oncol Lett"},{"issue":"1","key":"10.1016\/j.humpath.2026.106281_bib13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1464-410X.2002.02526.x","article-title":"Gene amplification and overexpression of HER2 in renal cell carcinoma","volume":"89","author":"Latif","year":"2002","journal-title":"BJU Int"},{"issue":"11","key":"10.1016\/j.humpath.2026.106281_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113345","article-title":"Assessment of HER2 protein overexpression and gene amplification in renal collecting duct carcinoma: therapeutic implication","volume":"12","author":"Costantini","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"22","key":"10.1016\/j.humpath.2026.106281_bib15","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-college of American pathologists guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.humpath.2026.106281_bib16","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.humpath.2026.106281_bib17","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/PAS.0000000000000626","article-title":"Immunohistochemistry for 2-Succinocysteine (2SC) and fumarate hydratase (FH) in cutaneous leiomyomas may aid in identification of patients with HLRCC (hereditary leiomyomatosis and renal cell carcinoma syndrome)","volume":"40","author":"Buelow","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.humpath.2026.106281_bib18","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/PAS.0000000000000163","article-title":"Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry","volume":"38","author":"Chen","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1016\/j.humpath.2026.106281_bib19","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/PAS.0000000000000617","article-title":"Fumarate hydratase-deficient renal cell carcinoma is strongly correlated with fumarate hydratase mutation and hereditary leiomyomatosis and renal cell carcinoma syndrome","volume":"40","author":"Trpkov","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1016\/j.humpath.2026.106281_bib20","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/modpathol.2009.37","article-title":"Validation of the 4B5 rabbit monoclonal antibody in determining Her2\/neu status in breast cancer","volume":"22","author":"van der Vegt","year":"2009","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.humpath.2026.106281_bib21","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the college of American pathologists, American society for clinical pathology, and the American society of clinical oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.humpath.2026.106281_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105310","article-title":"Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low\/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06","volume":"10","author":"Shami","year":"2025","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.humpath.2026.106281_bib23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00428-025-04111-8","article-title":"Clinicopathological and molecular features of so-called low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma: a study of 5 cases","volume":"487","author":"Xie","year":"2025","journal-title":"Virchows Arch"},{"issue":"5","key":"10.1016\/j.humpath.2026.106281_bib24","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1365-2559.2011.04034.x","article-title":"Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies","volume":"59","author":"Schrohl","year":"2011","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.humpath.2026.106281_bib25","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.bbrc.2017.01.086","article-title":"Development of a highly specific HER2 monoclonal antibody for immunohistochemistry using protein microarray chips","volume":"484","author":"Qi","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"10.1016\/j.humpath.2026.106281_bib26","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41571-024-00924-9","article-title":"HER2-targeted therapies beyond breast cancer - an update","volume":"21","author":"Yoon","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.humpath.2026.106281_bib27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2559.2011.03760.x","article-title":"HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH)","volume":"58","author":"Boers","year":"2011","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2026.106281_bib28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4137\/CMO.S10811","article-title":"Cytoplasmic overexpression of HER2: a key factor in colorectal cancer","volume":"7","author":"Blok","year":"2013","journal-title":"Clin Med Insights Oncol"},{"issue":"6","key":"10.1016\/j.humpath.2026.106281_bib29","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.21037\/gs-22-248","article-title":"Tumor-infiltrating lymphocytes status, programmed death-ligand 1 expression, and clinicopathological features of 41 cases of pure apocrine carcinoma of the breast: a retrospective study based on clinical pathological analysis and different immune statuses","volume":"11","author":"Xiao","year":"2022","journal-title":"Gland Surg"},{"issue":"1","key":"10.1016\/j.humpath.2026.106281_bib30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/0008-5472.CAN-16-1656","article-title":"HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone","volume":"77","author":"Day","year":"2017","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.humpath.2026.106281_bib31","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s00428-003-0769-3","article-title":"Her2\/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease","volume":"442","author":"Kremser","year":"2003","journal-title":"Virchows Arch"},{"issue":"2","key":"10.1016\/j.humpath.2026.106281_bib32","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00428-020-02871-z","article-title":"Nuclear ErbB2 expression in hepatocytes in liver disease","volume":"478","author":"Doring","year":"2021","journal-title":"Virchows Arch"},{"issue":"9","key":"10.1016\/j.humpath.2026.106281_bib33","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/modpathol.2010.115","article-title":"Prognostic significance of HER2 expression in neuroblastic tumors","volume":"23","author":"Izycka-Swieszewska","year":"2010","journal-title":"Mod Pathol"},{"issue":"11","key":"10.1016\/j.humpath.2026.106281_bib34","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00383-006-1762-0","article-title":"Association between the HER2 expression and histological differentiation in Wilms tumor","volume":"22","author":"Salem","year":"2006","journal-title":"Pediatr Surg Int"},{"issue":"3","key":"10.1016\/j.humpath.2026.106281_bib35","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ccr.2004.07.012","article-title":"Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2","volume":"6","author":"Wang","year":"2004","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.humpath.2026.106281_bib36","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1158\/0008-5472.CAN-10-3504","article-title":"Nuclear ErbB2 enhances translation and cell growth by activating transcription of ribosomal RNA genes","volume":"71","author":"Li","year":"2011","journal-title":"Cancer Res"},{"issue":"24","key":"10.1016\/j.humpath.2026.106281_bib37","doi-asserted-by":"crossref","first-page":"11005","DOI":"10.1128\/MCB.25.24.11005-11018.2005","article-title":"Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor","volume":"25","author":"Giri","year":"2005","journal-title":"Mol Cell Biol"},{"issue":"13","key":"10.1016\/j.humpath.2026.106281_bib38","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1158\/1078-0432.CCR-22-0283","article-title":"Molecular pathways and mechanisms of HER2 in cancer therapy","volume":"29","author":"Raghav","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.humpath.2026.106281_bib39","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.clbc.2025.07.016","article-title":"Study on different staining platforms for HER2 cytoplasmic granular staining pattern in pure apocrine carcinoma of the breast","volume":"26","author":"Xiao","year":"2025","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"10.1016\/j.humpath.2026.106281_bib40","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.cmet.2016.10.008","article-title":"Glutaminolysis and fumarate accumulation integrate immunometabolic and epigenetic programs in trained immunity","volume":"24","author":"Arts","year":"2016","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.humpath.2026.106281_bib41","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.celrep.2013.09.009","article-title":"Chromatin modifications sequentially enhance ErbB2 expression in ErbB2-positive breast cancers","volume":"5","author":"Mungamuri","year":"2013","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.humpath.2026.106281_bib42","doi-asserted-by":"crossref","first-page":"E282","DOI":"10.1073\/pnas.1516138113","article-title":"PMCA2 regulates HER2 protein kinase localization and signaling and promotes HER2-mediated breast cancer","volume":"113","author":"Jeong","year":"2016","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817726002509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817726002509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:42:56Z","timestamp":1794314576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817726002509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":42,"alternative-id":["S0046817726002509"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2026.106281","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aberrant HER2 expression as a specific and feasible diagnostic marker for fumarate hydratase-deficient renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2026.106281","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106281"}}